加巴喷丁恩那卡比(gabapentin enacarbil,商品名Horizant)于2011年4月经美国食品药品管理局(FDA)批准上市,用于治疗中度至重度不宁腿综合征(restless legssyndromes,RLS)[1],该药物最初由美国XenoPort公司研发,之后由英国葛兰素史克公司(GlaxoSmithKline)通过并 Gabapentin enacarbil (Horizant) was approved by the U.S. Food and Drug Administration (FDA) in April 2011 for the treatment of moderate to severe restless legss syndrome (RLS) [1] , Originally developed by XenoPort in the United States and subsequently adopted by GlaxoSmithKline